BRPI0412255A - tratamento da disfunção sexual masculina - Google Patents
tratamento da disfunção sexual masculinaInfo
- Publication number
- BRPI0412255A BRPI0412255A BRPI0412255-0A BRPI0412255A BRPI0412255A BR PI0412255 A BRPI0412255 A BR PI0412255A BR PI0412255 A BRPI0412255 A BR PI0412255A BR PI0412255 A BRPI0412255 A BR PI0412255A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- sexual dysfunction
- male sexual
- ejaculation
- relates
- Prior art date
Links
- 206010057672 Male sexual dysfunction Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010036596 premature ejaculation Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000000908 Vasopressin V1A receptors Human genes 0.000 abstract 1
- 108050007942 Vasopressin V1A receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
"TRATAMENTO DA DISFUNçãO SEXUAL MASCULINA". A presente invenção refere-se -se à utilização de antagonistas de receptores de vasopressina V1a para o tratamento da disfunção sexual masculina, em particular distúrbios de ejaculação, tal como ejaculação precoce ou ejaculação rápida. A presente invenção também refere-se a um método de tratamento da disfunção sexual masculina, em particular distúrbios de ejaculação, tal como ejaculação precoce ou ejaculação rápida. A presente invenção também refere-se a ensaios para pesquisar os compostos úteis no tratamento da disfunção sexual masculina, em particular distúrbios de ejaculação, tal como ejaculação precoce ou ejaculação rápida, por pesquisa de compostos que são antagonistas de receptores de V1a.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0317227.7A GB0317227D0 (en) | 2003-07-23 | 2003-07-23 | Treatment of male sexual dysfunction |
| PCT/IB2004/002300 WO2005006899A1 (en) | 2003-07-23 | 2004-07-12 | Treatment of male sexual dysfunction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0412255A true BRPI0412255A (pt) | 2006-09-19 |
Family
ID=27772516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0412255-0A BRPI0412255A (pt) | 2003-07-23 | 2004-07-12 | tratamento da disfunção sexual masculina |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1656183B1 (pt) |
| JP (1) | JP2006528171A (pt) |
| AT (1) | ATE380048T1 (pt) |
| BR (1) | BRPI0412255A (pt) |
| CA (1) | CA2533177A1 (pt) |
| CL (1) | CL2004001702A1 (pt) |
| GB (1) | GB0317227D0 (pt) |
| MX (1) | MXPA05014200A (pt) |
| TW (1) | TW200510424A (pt) |
| UA (1) | UA79674C2 (pt) |
| WO (1) | WO2005006899A1 (pt) |
| ZA (1) | ZA200505957B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS52625B (sr) | 2003-07-23 | 2013-06-28 | Bayer Healthcare Llc | Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti |
| GB0504556D0 (en) * | 2005-03-04 | 2005-04-13 | Pfizer Ltd | Novel pharmaceuticals |
| WO2006100557A1 (en) * | 2005-03-21 | 2006-09-28 | Pfizer Limited | Substituted triazole derivatives as oxytocin antagonists |
| US20220152032A1 (en) * | 2020-11-13 | 2022-05-19 | Pharma America Holding Inc. | Sexual therapy formulation and method of treatment |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2000223275A1 (en) * | 2000-02-08 | 2001-08-20 | Yamanouchi Pharmaceutical Co..Ltd. | Novel triazole derivatives |
| GB0224919D0 (en) * | 2002-10-25 | 2002-12-04 | Pfizer Ltd | Triazole compounds useful in therapy |
-
2003
- 2003-07-23 GB GBGB0317227.7A patent/GB0317227D0/en not_active Ceased
-
2004
- 2004-07-06 CL CL200401702A patent/CL2004001702A1/es unknown
- 2004-07-12 BR BRPI0412255-0A patent/BRPI0412255A/pt not_active IP Right Cessation
- 2004-07-12 WO PCT/IB2004/002300 patent/WO2005006899A1/en not_active Ceased
- 2004-07-12 JP JP2006520920A patent/JP2006528171A/ja not_active Abandoned
- 2004-07-12 AT AT04743961T patent/ATE380048T1/de not_active IP Right Cessation
- 2004-07-12 MX MXPA05014200A patent/MXPA05014200A/es unknown
- 2004-07-12 EP EP04743961A patent/EP1656183B1/en not_active Expired - Lifetime
- 2004-07-12 CA CA002533177A patent/CA2533177A1/en not_active Abandoned
- 2004-07-19 TW TW093121513A patent/TW200510424A/zh unknown
- 2004-09-02 UA UAA200508142A patent/UA79674C2/uk unknown
-
2005
- 2005-07-25 ZA ZA200505957A patent/ZA200505957B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05014200A (es) | 2006-07-03 |
| ZA200505957B (en) | 2006-11-29 |
| EP1656183A1 (en) | 2006-05-17 |
| WO2005006899A1 (en) | 2005-01-27 |
| TW200510424A (en) | 2005-03-16 |
| CL2004001702A1 (es) | 2005-05-13 |
| ATE380048T1 (de) | 2007-12-15 |
| JP2006528171A (ja) | 2006-12-14 |
| EP1656183B1 (en) | 2007-12-05 |
| CA2533177A1 (en) | 2005-01-27 |
| GB0317227D0 (en) | 2003-08-27 |
| UA79674C2 (en) | 2007-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200901099A1 (ru) | Соединения и способы модулирования сопряженных с g-белком рецепторов | |
| CY1111927T1 (el) | Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων | |
| EA200702617A1 (ru) | Антагонисты мускариновых ацетилхолиновых рецепторов | |
| CY1117228T1 (el) | Διεργασια για την παρασκευη συνθεσεων υδροχλωρικης οξυκωδονης που εχουν λιγοτερο απο 25 ppm 14-υδροξυκωδεϊνονη | |
| CR9291A (es) | Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il-17f, y sus usos | |
| TW200510301A (en) | Novel compounds | |
| TW200510303A (en) | Novel compounds | |
| MXPA03007513A (es) | Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato. | |
| MXPA06014798A (es) | Antagonistas del receptor de hormona para liberar gonadotropina. | |
| SE0203713D0 (sv) | Novel compounds | |
| TNSN07195A1 (en) | Potentiators of glutamate receptors | |
| CL2004000545A1 (es) | Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul | |
| PL1636221T3 (pl) | Związki 3-heterocyklilo-azetydynowe użyteczne jako antagoniści receptorów NK1/NK2 | |
| TW200420543A (en) | Treatment of female sexual dysfunction | |
| TW200621244A (en) | Modulators of muscarinic receptors | |
| NO20073369L (no) | Modulatorer av muskarinreseptorer | |
| EA200701979A1 (ru) | Способ получения опиоидных модуляторов | |
| TW200800959A (en) | Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor | |
| EA200600688A1 (ru) | Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а | |
| BRPI0412255A (pt) | tratamento da disfunção sexual masculina | |
| WO2002100350A3 (en) | Dopamine receptor ligands and therapeutic methods based thereon | |
| WO2007014263A3 (en) | Octahydroisoquinoline compounds as opioid receptor modulators | |
| MXPA05012572A (es) | Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central. | |
| CL2004001507A1 (es) | Compuestos derivados de espirobenzobenzazepinas sustituidos, inhibidores de receptores de vasopresina; composicion farmaceutica; utiles en el tratamiento de hipertension, disfuncion cardiaca, insuficiencia renal, entre otras. | |
| EA200801591A1 (ru) | Антагонисты мускаринового рецептора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |